Onco Actu du 17 janvier 2019

	1. BIOLOGIE
Study of Mutation Order May Change Understanding of How Tumors Develop [Institute for Advanced Study] Cancer Cell Paper Envisions New Direction in Cancer Research.
Cryptic DNA sequences may help cells survive starvation [Nature] Stretches of non-coding DNA in genes called introns could have an important survival function.
	2.4 ETIOLOGIE - PORTABLES, ONDES E-M
Italian Court Orders Public Safety Campaign [Microwave News] In a victory for advocates of precaution, an Italian court has ordered the government to launch a campaign to advise the public of the health risks from mobile and cordless phones. The information campaign must begin by July 16.
	2.6 ETIOLOGIE - ENVIRONNEMENT
Do shop receipts contain cancer-causing chemicals? [NHS Choices] The study does suggest BPA in thermal paper may have hormonal activity, but we do not know how much BPA transfers from receipts into the human body with normal use. Most importantly, we do not really know the effects of BPA on the human body.
	3.1.1 PRÉVENTION - TABAC - E-CIGS
Japan Tobacco ratchets up smokeless war with new products [Reuters] Japan Tobacco Inc unveiled two “heat-not-burn” products, as it races against market leader Philip Morris International Inc for a larger share of the vaping space with conventional cigarettes steadily falling out of favor.
	5. TRAITEMENTS
U.S. Preventive Services Task Force Issues Draft Recommendation Statement on Medication Use to Reduce Risk of Breast Cancer [USPTF] Clinicians should offer risk-reducing medications to women at increased risk for breast cancer and at low risk for adverse medication effects.
	5.12 IMMUNOTHÉRAPIES
Blocking PD-L1 production in mice, UCSF team spotlights preclinical promise of a Pfizer-backed I/O drug [EndPoints] Ruggero and his team took into a preclinical trial a compound known as eFT508 — now in Phase II as both a monotherapy and an add-on to checkpoints — which inhibits eIF4E, a cellular “translation factor” they say is responsible for pairing RNA with ribosomes.
Merck And The Future of Immuno-Oncology: A Chat With Roger Perlmutter [Xconomy] I would like a much more thorough molecular, cellular description of what happens in a cancer patient who responds to Keytruda. What are the T cells doing that are responsible for this good work? An understanding of those cells could be enormously helpful in getting better combinations with Keytruda. Thus far it’s an embarrassment to say—and I’m embarrassed for the entire scientific community—none of us have been able to achieve this.
	5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
Dragonfly preps clinical takeoff, inking a collaboration pact with MD Anderson [EndPoints] Dragonfly’s platform centers on TriNKETs (Tri-specific, NK cell Engager Therapies), a binding mechanism that links natural killer cells to the proteins found on the surface of cancer cells.
	5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
US regulator to recruit 50 new gene and cell therapy clinical reviewers [Pharmafile] There are currently 800 active cell-based or directly administered gene therapy investigational new drug (IND) applications on file while the FDA anticipates an additional 200 INDs per year by 2020.
	5.12.5 IMMUNOTHÉRAPIES - PHARMA
Merck bumps Keytruda credibility with real doctor appearance in latest ‘Tru’ patient ads [Fierce Pharma] In the two years since Merck first began advertising Keytruda on TV, it has spent $234 million on national TV ad buys, according to data from real-time TV ad tracker iSpot.tv. Merck is among several immunotherapy cancer drug makers who have taken their marketing messages to mainstream TV.
FDA accepts Roche’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer [Roche] This sBLA is based on results from the Phase III IMpower130 study, which met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) in the initial treatment of people with metastatic non-squamous NSCLC.
	5.2.3 PHARMA - ÉCONOMIE
Five Prime cuts 41 jobs, narrows focus to clinical-stage drugs [Fierce Biotech] The biotech’s phase 3 candidate bemarituzumab for stomach cancer, a fibroblast growth factor receptor 2 inhibitor partnered with Chinese company Zai Lab, is on the ASCO GI presentation list, along with colony stimulating factor 1 receptor antibody cabiralizumab it is developing with long-term partner Bristol-Myers Squibb.
Five Prime cuts 41 jobs, days before presenting data at ASCO meeting of GI cancers [EndPoints] Things have not been the same at cancer-focused drug developer Five Prime Therapeutics since late 2017, when its Bristol-Myers $BMY partnered drug cabiralizumab in combination with Opdivo showed signs of weak efficacy and a troubling safety profile in an early-stage pancreatic cancer trial.
	5.4 TRAITEMENTS - ECONOMIE
The U.S. should assess the economic value of drugs rather than leave it up to other countries [STAT] By owning this critical task, we can protect American patients while restraining price hikes domestically. We can also prod other governments to consider how the U.S. values drugs, opening the door for greater cooperation and contributions to innovation.
	5.5.5 ASCO (GASTRO-INTESTINAL)
Bayer to Highlight New Research at ASCO GI 2019 Cancers Symposium [Bayer] New data includes the final analysis of the CORRELATE study in metastatic colorectal cancer.
	6.1 OBSERVATION
Teenage cancer survival 'on the up' in England, report finds [BBC News] When the report compared five-year survival rates for those diagnosed between 2001-05 and 2007-11, it found they had risen from 83% to 87% for females and 80% to 84% for males.
	6.12 ETHIQUE
Memorial Sloan Kettering Curbs Executives’ Ties to Industry After Conflict-of-Interest Scandals [NY Times] Debra Berns, the center’s chief risk officer, also said in an email to employees that the hospital’s Board of Overseers and Managers formalized a policy enacted last fall that prohibits board members from investing in start-up companies that Memorial Sloan Kettering helped to found. In addition, it also prevents hospital employees who represent Memorial Sloan Kettering on corporate boards from accepting personal compensation, like equity stakes or stock options, from the companies.
	6.6 PUBLICATIONS
Wiley and Projekt DEAL partner to enhance the future of scholarly research and publishing in Germany [Wiley] The Projekt DEAL project was set up by the Alliance of Science Organisations in Germany representing the vast majority of the most important science and research organisations in Germany. The consortium includes nearly 700 mostly publicly funded academic institutions in Germany such as universities, universities of applied sciences, research institutions and state and regional libraries.
German Institutions and Wiley Reach Open-Access Publishing Deal [The Scientist] The three-year contract, in which all articles will be published as open access in exchange for an annual fee for journal subscriptions, is a triumph for Project DEAL.
	6.7.2 APPLIS
Apple's health boss leaves for new start-up, fulfilling a promise he made to his sick sister [CNBC] Sethi had taken some months off to help his sister fight cancer, and promised her before she died that he would do something to help very sick patients. Ciitizen will help patients get and share information like genomic information, labs, ethical wills or advanced directives.